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Fabry disease is a rare lysosomal storage disorder (LSD). We
designed multiple recombinant lentivirus vectors (LVs) and
tested their ability to engineer expression of human a-galac-
tosidase A (a-gal A) in transduced Fabry patient CD34+
hematopoietic cells. We further investigated the safety and
efﬁcacy of a clinically directed vector, LV/AGA, in both
ex vivo cell culture studies and animal models. Fabry mice
transplanted with LV/AGA-transduced hematopoietic cells
demonstrated a-gal A activity increases and lipid reductions
in multiple tissues at 6 months after transplantation. Next we
found that LV/AGA-transduced Fabry patient CD34+ he-
matopoietic cells produced even higher levels of a-gal A
activity than normal CD34+ hematopoietic cells. We success-
fully transduced Fabry patient CD34+ hematopoietic cells
with “near-clinical grade” LV/AGA in small-scale cultures
and then validated a clinically directed scale-up transduc-
tion process in a GMP-compliant cell processing facility.
LV-transduced Fabry patient CD34+ hematopoietic cells
were subsequently infused into NOD/SCID/Fabry (NSF)
mice; a-gal A activity corrections and lipid reductions were
observed in several tissues 12 weeks after the xenotransplan-
tation. Additional toxicology studies employing NSF mice
xenotransplanted with the therapeutic cell product demon-
strated minimal untoward effects. These data supported
our successful clinical trial application (CTA) to Health Can-
ada and opening of a “ﬁrst-in-the-world” gene therapy trial
for Fabry disease.
INTRODUCTION
Fabry disease (OMIM no. 301500) occurs because of a deﬁciency of
a-galactosidase A (a-gal A; EC 3.2.1.22) activity.1 Glycosphingolipids
such as globotriaosylceramide (Gb3) accumulate in Fabry disease.
This build-up ultimately leads to end-organ damage in the kidneys,
heart, and brain.2 The GLA gene that encodes for a-gal A is found
on the X chromosome; both men and heterozygous women have clin-
ical manifestations of Fabry disease. Life expectancy with Fabry dis-
ease is decreased in males to 58.2 years and in females to 75.4 years.3
The prevalence of males with Fabry disease ranges from 1:17,000 to
1:117,000 in the Caucasian population.4,5 Recent newborn screening
studies have, however, indicated a much higher incidence of this dis-
order because patients with later onset and milder forms of Fabry dis-
ease are found even more commonly than expected, suggesting that
they are possibly underdiagnosed.6–13
Enzyme replacement therapy (ERT) is the only Food and Drug
Administration (FDA)-approved treatment for Fabry disease
to date. Last year, oral pharmacological chaperone therapy was
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approved by the European Commission to treat Fabry patients in the
European Union (EU) with an amenable mutation of a-gal A.14 Our
group and others have been developing gene therapy for this disorder
for nearly 20 years.15–23 We previously showed that “metabolic coop-
erativity” or “cross-correction” occurs for Fabry disease. This means
that genetically augmented cells are not only corrected enzymatically
themselves but also facilitate extracellular secretion of a-gal A that
can be taken up and used functionally by unmodiﬁed bystander
cells.17,20 Our previous studies in Fabry mice showed that metabolic
cooperativity is manifested in multiple organs over long periods of
time (even in secondary recipient animals) following genetic correc-
tion of primitive hematopoietic cells.24 Therefore, targeting CD34+
hematopoietic stem cells (HSCs)/progenitor cells for gene augmenta-
tion is a promising strategy to achieve long-term enzyme correction
in the blood and organs in patients with Fabry disease. We have
also developed the non-obese diabetic (NOD)/severe combined im-
munodeﬁciency (SCID)/Fabry (NSF) mouse model for in vivo efﬁ-
cacy and toxicity studies with our lentivirus (LV) vector-transduced
human cell product.15
Here we constructed multiple novel recombinant LV vectors in a
sequential fashion that engineered expression of a-gal A and
compared their functionality following ex vivo transduction of mobi-
lized Fabry patient CD34+ hematopoietic cells. This was done in prep-
aration for a clinical trial application (CTA) to Health Canada. Two
early-version vectors that contained a “cell-fate control” or “suicide”
element and/or a cell surface marker sequence only yielded 10%–30%
a-gal A activity of that seen in control normal cells. A later-generation
construct (LV/AGA) consisting of only the human codon-optimized
GLA cDNA with a canonical Kozak sequence produced higher-than-
normal levels of a-gal A in transduced Fabry patient CD34+ hemato-
poietic cells. This vector was used as the “clinically directed reagent”
going forward for all our preclinical efﬁcacy and safety studies. This
vector was also tested in long-term Fabry mouse-to-Fabry mouse ex-
periments; no untoward effects were seen, and enzyme correction/
lipid reduction were observed.
Next we developed a translatable protocol to successfully transduce
Fabry patient CD34+ hematopoietic cells ex vivo with a “near-clin-
ical-grade” preparation of LV/AGA. The vector was made by the In-
diana University Vector Production Facility (IUVPF). Transduced
cells were subsequently infused into NSF mice. A signiﬁcant increase
in a-gal A activity was observed in the plasma, bone marrow, spleens,
and livers of transplanted NSF mice. Mass spectrometry (MS) results
showed a reduction of total Gb3 levels in spleens and livers. Following
this, we performed an independent toxicology study on xenotrans-
planted NSF mice and observed minimal in vivo perturbations from
the therapeutic cell product. Finally, we validated scale-up transduc-
tion experiments in a cell processing facility at the University Health
Network (UHN) under good manufacturing practices (GMP) condi-
tions to meet CTA requirements. Our preclinical data in animals and
validated scale-up LV-transduction processes, utilizing CD34+ he-
matopoietic cells, provided essential evidence to support opening of
a phase I gene therapy trial to treat patients with Fabry disease.
RESULTS
Ex Vivo Transduction of CD34+ Hematopoietic Cells with
Multiple LV Iterations and Development of a Clinically Directed
Product
We had previously constructed an LV transfer vector, pDY.DLNGFR/
TMPK.IRES.CO.a-gal A, which is a bicistronic vector comprised of
the cDNA of a cell-fate control element, DLNGFR/modiﬁed human
thymidylate kinase (TMPK) as the ﬁrst transgene, followed by an in-
ternal ribosome entry site (IRES), and then the cDNA of the human
GLA gene encoding normal a-gal A enzyme—all under the control of
the mammalian elongation factor 1 a (EF-1a) promoter.16 The cDNA
of the DLNGFR/TMPK component encodes a fusion form of
the truncated human low-afﬁnity nerve growth factor receptor
(DLNGFR) combined with mutant TMPK. DLNGFR serves as a
cell surface protein marker, and the mutant TMPK induces cell death
by downstream-phosphorylating the prodrug 30-azido-30-deoxythy-
midine (AZT) to AZT-DP and, thus, is a “suicide gene” when trans-
duced cells need to be eliminated for any reason.15 Furthermore, the
cDNAs of both the DLNGFR/TMPK element and the human GLA
sequence were codon-optimized to enhance expression in human
cells. The LV produced from this transfer vector (LV/FAB) has
been previously shown by us to engineer good a-gal A expression
in Fabry patient B cells and in supernatants from transduced normal
CD34+ hematopoietic cells. Such transductions also rendered cells
sensitive to AZT treatment.16
Near-clinical-grade LV/FAB was produced under contract with the
IUVPF in a GMP facility. The near-clinical-grade vector was manu-
factured in the same facility and follows the same procedures as the
clinical-grade vector that is being used for our phase I gene therapy
trial in Fabry patients (https://clinicaltrials.gov, NCT02800070). Pro-
cessing is the same, except that the latter version has more extensive
quality control/quality assurance testing and documentation.
We ﬁrst examined the transduction ﬁdelity and functionality of LV/
FAB in ex vivo-cultured mobilized peripheral blood CD34+ hemato-
poietic cells collected from a classically affected male Fabry patient
(no. 14-159) following our protocol as described in Materials and
Methods. Normal CD34+ hematopoietic cells from healthy donors
were included in parallel as a positive control. Secreted (culture super-
natant) and intracellular (cell lysate) a-gal A activity was measured.
We found an efﬁcient transduction frequency of 65%–85% in Fabry
patient CD34+ hematopoietic cells by staining for truncated LNGFR
expression followed by ﬂow cytometry analyses (Figure S1A). Mock-
transduced Fabry patient CD34+ hematopoietic cells (MOI = 0)
showed minimal a-gal A activity in cell lysates and negligible secreted
activity in the supernatant (Figures S1B and S1C). Unfortunately, LV/
FAB-transduced Fabry patient CD34+ hematopoietic cells only
demonstrated a small increase in a-gal A activity, to10% of the level
seen in normal CD34+ cells, at anMOI of 18. Even with LV/FAB at an
MOI of 80, the level of a-gal A activity in transduced Fabry CD34+ he-
matopoietic cells only reached30%of that seen in normalCD34+ he-
matopoietic cells (Figure S1C). At this point, a decision was made that
this vector construct did not warrant progression into the clinic.
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We next examined the DNA sequence of the transfer vector used
above and found that the sequence surrounding the start codon of
the GLA cDNA (CCCACC) was not the canonical eukaryotic Kozak
consensus sequence (GCC(AorG)CC), which has a conserved G at
the 6-bp position from the start codon.25 Therefore, we adjusted
the sequence surrounding the start codon in the LV/FAB transfer vec-
tor and made a new LV preparation in our laboratory. This new
research-grade LV/FAB-2 performed slightly better in CD34+ he-
matopoietic cells, enabling transduced Fabry patient cells to secrete
a similar or higher level of a-gal A enzyme (at MOI 18 and 80)
than normal cells (Figure S1B). However, intracellular a-gal A activity
from LV/FAB-2-transduced Fabry patient CD34+ hematopoietic cells
was still only 10% of that observed from normal cells (Figure S1C).
In parallel with the preceding studies, we compared another vector,
LV/a-gal A.IRES.hCD25, which had been constructed and used pre-
viously in our lab.15,26 This vector consisted of an EF-1a promoter-
driven cDNA encoding wild-type human a-gal A followed by an
IRES.hCD25 sequence.26 We found that Fabry CD34+ hematopoietic
cells transduced with this vector produced higher levels of a-gal A
than LV/FAB and LV/FAB-2 in both medium supernatant and cell
lysates (Figures S1B and S1C). Even though the secreted level of
a-gal A activity from LV/a-gal A.IRES.hCD25-tranduced Fabry pa-
tient CD34+ hematopoietic cells reached 1.2- to 4.2-fold higher
than that from normal cells, the intracellular level of a-gal A activity
was still only 17%–31% of normal cells depending on the MOI used
(Figures S1B and S1C). These results suggest that the bicistronic vec-
tor orientation (speciﬁcally the inclusion of an IRES element) may
affect the efﬁciency of downstream a-gal A translation in transduced
CD34+ hematopoietic cells.
To develop a more efﬁcient LV that can produce higher levels of a-gal
A in transduced target CD34+ hematopoietic cells and fulﬁll our
clinical directive, we constructed another new transfer vector,
pDY.CO.a-gal A (LV/AGA), consisting of a codon-optimized
cDNA of human GLA under the control of the EF-1a promoter (Fig-
ure 1A). This vector also maintains the optimized Kozak sequence
around the initiation codon. A LV using this simplest transfer vector
(LV/AGA)was prepared in our laboratory (research-grade) and tested
for transduction of Fabry CD34+ hematopoietic cells (patient no. 14-
159). As shown in Figures S1B and S1C, LV/AGA-transduced Fabry
cells showed signiﬁcantly increased a-gal A activity in both the super-
natant (4.6-fold over normal cells) and the cell lysates. In fact, a-gal A
activity levels in lysates from cell pellets that had been infected at an
MOI of 10 were even higher than those observed in normal cells.
Transduced cells showed lower a-gal A activity at an MOI of 50
than what was observed at an MOI of 10, suggesting some sort of in-
hibition or a toxic effect on cells at higher MOIs using this research-
grade vector preparation. We repeated the transduction experiment
twomore times at anMOI of 10 on the same patient cells and obtained
similar results (Figure 1B). Therefore, we decided to use LV/AGA as
the vector for the rest of the pre-clinical studies and for a subsequent
phase I gene therapy trial treating Fabry patients (which has now been
approved by Health Canada; see https://clinicaltrials.gov).
We also investigated the optimal MOI for transduction with the clin-
ically directed vector. Fabry patient CD34+ hematopoietic cells were
transduced with research-grade LV/AGA at MOIs of 0, 5, 10, 15,
and 20. a-Gal A activity in lysates from transduced target cells
increased with MOIs up to 10, and then the enzyme activity again
reduced at MOIs of 15 and 20 (Figure 1D); hence, we decided to
use an MOI of 10 for transductions in the rest of the study to achieve
maximal efﬁcacy.
Pre-clinical Validations of LV/AGA In Vitro in Fabry Patient CD34+
Hematopoietic Cells
Near-clinical-grade LV/AGA was subsequently produced by IUVPF
as described in Materials and Methods. This product was tested by
transduction of mobilized CD34+ hematopoietic cells from a healthy
donor as well as from two Fabry patients (nos. 14-159 and 15-220).
The results are shown in Figures 1C and 1E, respectively. Consistent
with the results from research-grade LV/AGA, both secreted and
intracellular a-gal A activities were minimal in mock-transduced
Fabry cells but substantially elevated in LV/AGA-transduced Fabry
cells to a level 20% higher than mock-transduced normal cells (Fig-
ures 1C and 1E). Furthermore, a-gal A activity from LV/AGA-trans-
duced normal cells was also more than 2-fold higher than the a-gal A
activity from mock-transduced normal cells (Figure 1C).
To determine the core near-clinical-grade LV/AGA transduction
efﬁciency of the CD34+ hematopoietic cells, we examined average
viral copy number (VCN) per genome by qPCR along with the
percentage of LV-positive cells by colony-forming cell (CFC) as-
says (Table 1). An average of 0.25, 0.43, and 0.33 VCNs/genome
were obtained from transduced normal, transduced Fabry patient
no. 14-159, and transduced Fabry patient no. 15-220 cells, respec-
tively. As negative controls, 0 VCN/genome was obtained from all
mock-transduced cells. To evaluate the transduction frequency of
CD34+ stem/progenitor cells using our protocol, we performed
CFC assays by growing LV-transduced cells in methylcellulose
and testing for the percentage of LV-integrated cell-derived col-
onies as described in Materials and Methods. Forty-six percent
(26 of 56 colonies) and 20% (22 of 111 colonies) of LV/AGA-trans-
duced cells corresponding to Fabry patient no. 14-159 and Fabry
patient no. 150-220 samples, respectively, were positive for the
woodchuck hepatitis virus post-transcriptional regulatory element
(WPRE) (LV-derived), consistent with the aforementioned VCN
results.
These data show that, at an MOI of 10, 20%–50% of primitive he-
matopoietic cells had stable LV/AGA integration, and those trans-
duced cells expressed a-gal A activities to the level of that observed
in extracts from normal human CD34+ hematopoietic cells.
Safety and Efficacy of Clinically Directed LV/AGA in Fabry
Mouse-to-Fabry Mouse Experiments
To investigate the long-term efﬁcacy of LV/AGA and our cell product
and to ensure that there were no untoward effects in vivo from this
recombinant vector, we carried out mouse-to-mouse bone marrow
www.moleculartherapy.org
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transplant (BMT) experiments in a previously established Fabry
mouse model.27 We have performed analogous experiments before
but with a different Fabry LV construct.24 Basically, bone marrow
(BM) cells from donor Fabry mice were transduced overnight with
vehicle (mock) or research-grade LV/AGA at an MOI of 10. Male
recipient Fabry mice were lethally irradiated and injected with 1 
106 transduced cells via their tail veins. Peripheral blood was collected
every 4 weeks after BMT. a-Gal A activity was measured in the
A
B
C
D
E
Figure 1. Efficient Transduction of Mobilized Fabry
Patient CD34+ Hematopoietic Cells with LV/AGA
(A) Schematic of the LV transfer vector, pDY.CO.a-gal A
(i.e., LV/AGA), used in this study. LTR, long terminal
repeat;J, HIV packaging signal; SD, 50 splice donor site;
DGAG, deleted group antigens; RRE, Rev-responsive
element; SA, 30 splice acceptor site; cPPT, central poly-
purine tract; EF-1a, elongation factor 1 a promoter;
CO.a-gal A, codon-optimized cDNA of the human GLA
gene encoding the wild-type a-gal A enzyme; WPRE,
woodchuck hepatitis virus post-transcriptional regulatory
element; SIN/LTR, self-inactivating LTR. (B–E) CD34+
hematopoietic cells from a healthy donor (normal) or
Fabry patient (no. 14-159) were mock-transduced or
transduced with research-grade (B) or near-clinical-
grade (C) LV/AGA at an MOI of 10. Cell culture super-
natants and cell lysates were processed and assayed
for a-gal A activity either 2 days (B and D) or 4 days (C
and E) post-transduction as described in Materials and
Methods. The data presented in (B) are mean ± range
from two independent experiments (n = 1 for normal cells
and n = 2 for Fabry cells). (D) Fabry patient (no. 14-159)-
mobilized CD34+ hematopoietic cells were transduced
with the research-grade LV/AGA at MOIs of 0, 5, 10, 15,
and 20. a-Gal A activity was measured from cell culture
supernatants and cell lysates. (E) Mobilized CD34+
hematopoietic cells from a Fabry patient (no. 15-220)
were mock-transduced or transduced with the near-
clinical-grade LV/AGA, and a-gal A activity was
measured as in (C).
plasma and in lysates from peripheral blood
mononuclear cells (PBMCs) at each collection
point. Besides some cases of ulcerative derma-
titis, which can happen with lethal irradiation,
no untoward effects were observed in recipient
animals. Mice infused with LV/AGA-trans-
duced cells (LV/AGA group) had signiﬁ-
cantly higher a-gal A activity in their plasma
throughout 6 months post-BMT compared
with mice that received mock-transduced cells
(mock group) (Figure 2A). Similarly, a-gal A
activity in PBMCs and BM from the mock
group was only 3–6 nmol/hr/mg protein but
reached 30–35 nmol/hr/mg protein in PBMCs
and 120–220 nmol/hr/mg protein in BM of
the LV/AGA-treated group (Figure 2B). To
ascertain whether organs in transplanted Fabry
mice were corrected by transplantation of LV-modiﬁed BM cells, we
harvested spleens, livers, hearts, and kidneys at 3-month and 6-month
endpoints and measured a-gal A activity in tissue lysates. Lysates
from the mock group all showed minimal a-gal A activity, whereas
spleen, liver, and heart extracts from the LV/AGA group displayed
signiﬁcant elevations in a-gal A activity, ranging from a 10- to 20-
fold increase in spleens to a 17- to 47-fold increase in livers and a
10-fold increase in hearts (Figure 2C). In contrast, no a-gal A activity
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differences were observed in tissue lysates from the kidneys
(Figure 2D).
To examine whether transplantation of Fabry mice with LV/AGA-
transduced BM cells corrected substrate accumulation, we measured
total Gb3 levels in harvested organs by ultra-performance liquid chro-
matography tandem MS (UPLC-MS/MS). Representative chromato-
grams of 22 Gb3 isoforms analyzed from Fabry mouse spleen tissue
are shown in Figure S2. Consistent with elevated a-gal A activity in
spleens, livers, and hearts, total Gb3 levels in these organs were signif-
icantly reduced from 1,000–4,000 (area/area internal standard [IS]) in
mice from the mock group to 40–250 (area/area IS) in mice from
the LV/AGA-treated group (Figure 2D). Gb3 levels in kidney extracts
from the LV/AGA group also trended toward a decrease compared
with the mock group, although the reduction was not statistically sig-
niﬁcant. These results demonstrated that LV/AGA was safe and engi-
neered expression of functional a-gal A in LV/AGA BMT-treated
Fabry mice for up to 6 months (the endpoint of the study); expression
of this transgene also efﬁciently reduced Gb3 levels in several major
organs.
To evaluate the long-term in vivo persistence of LV/AGA integration
in transduced cells, we examined average VCN in collected PBMCs,
BM, and organs from the Fabry mouse-to-mouse transplant experi-
ments after cells/tissues were lysed and genomic DNA was extracted
(Materials and Methods). An average of 0.5–1.5 VCN/genome was
detected in PBMCs and BM at each time point up to 6 months
post-transplantation (the endpoint of the study). Cells from the
spleen had 0.5 VCN/genome, cells from the liver and heart had
0.1–0.2 VCN/genome, and cells from the kidney had 0.05 VCN/
genome. These results are consistent with the a-gal A activity results:
organs with higher VCNs showed higher enzyme activity.
Testing the Safety and Efficacy of LV/AGA-Transduced,
Mobilized Fabry Patient CD34+ Hematopoietic Cells In Vivo in an
NSF Xenograft Model
Our group previously established the NSF mouse model, which is
immunodeﬁcient and lacks a-gal A activity.15 Our previous study
demonstrated successful xenotransplantation of normal human
CD34+ hematopoietic cells in this mouse model.15 To examine
whether LV/AGA-transduced Fabry patient CD34+ hematopoietic
cells could persist and produce functional a-gal A activity in vivo,
we carried out xenograft experiments in our NSF mice. Mice were
preconditioned by semi-lethal irradiation and injected intraperitone-
ally with a monoclonal antibody raised against mouse CD122 to
deplete natural killer (NK) cells.15 Then mice were infused with
mock or near-clinical-grade LV/AGA-transduced Fabry patient (no.
15-220) CD34+ hematopoietic cells via tail vein injections. Human
cell engraftment efﬁciencies were determined by staining isolated
PBMCs or BM from the mice with an antibody against human
CD45 (hCD45) followed by ﬂow cytometry analyses. An average of
5%–10% hCD45+ cells were detected in the peripheral blood, and
17%–20% hCD45+ cells were detected in the BM at the study
endpoint (Figures 3A and 3B). In addition, around 2% hCD34+ pro-
genitor cells were present in the BM 12 weeks after transplant
(Figure 3C). Overall, the human cell engraftment rate was very similar
between the animals receiving mock and LV/AGA-transduced Fabry
patient cells.
To investigate whether LV/AGA-transduced Fabry patient CD34+
hematopoietic cells produced a functional transgene product in the
xenotransplanted NSF mice, we measured a-gal A activity in the
plasma, BM, and major organs of recipient animals. The LV/AGA
group had signiﬁcantly higher a-gal A activity in the plasma than
the mock group 6 weeks after transplant (Figure 4A). The a-gal A
level peaked at 6 weeks and gradually dropped after that (Figure 4A),
suggesting rejection of the human cells by these mice because mature
NK cells are eventually re-generated. Levels of a-gal A activity in the
BM, spleen, and liver from the LV/AGA xenotransplanted group also
signiﬁcantly increased 20-fold, 2.5-fold, and 3.0-fold, respectively,
compared with the mock group (Figure 4B). Note that one animal
from the mock group was found with a lymphoma at the experi-
mental endpoint. a-Gal A activity in the plasma and in kidney lysates
from this animal were abnormally higher than in other mice from the
mock group at the study endpoint. The corresponding data points
derived from that animal for each tissue are circled in Figures 4A
and 4C.
In agreement with the increased a-gal A activity, total Gb3 levels from
the LV/AGA-transplanted group signiﬁcantly decreased in the spleen
and liver compared with the mock group. A trend toward Gb3 reduc-
tion was also found in hearts and kidneys, although these reductions
were not statistically signiﬁcant (Figure 4D). Transduced cells main-
taining proviral integration persisted up to 12 weeks post-transplant
(i.e., the endpoint of the study); an average of 0.2 VCN/genome
was detected in BM cells from the LV/AGA-treated group of mice.
Meanwhile, spleen cells showed 0.02 VCN per genome. Viral
copy numbers from livers, hearts, and kidneys were undetectable;
i.e., indistinguishable from the mock group (Figure 4E).
These results demonstrated that Fabry patient CD34+ hematopoi-
etic cells transduced with the near-clinical-grade therapeutic LV
Table 1. VCN and Transduction Efficiency in Small-Scale LV/AGA-Transduced Cells
Patient (No. 14-159) Patient (No. 15-220)
Samples Normal Mock Normal LV/AGA Fabry Mock Fabry LV/AGA Fabry Mock Fabry LV/AGA
VCN/genome 0 0.25 0 0.43 0 0.33
Percentage of transduced cells by CFC N/A N/A N/A 46 N/A 20
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Figure 2. In Vivo Correction of a-Gal A Deficiency by LV/AGA-Engineered Expression of Human a-Gal A in a Fabry Mouse-to-Fabry Mouse BMT Model
BM cells were harvested from donor Fabry mice, and BMMNCs were isolated as described in Materials and Methods. BMMNCs were transduced with vehicle (mock) or LV/
AGA and subsequently injected into lethally irradiated recipient Fabry male mice via the tail vein. Peripheral blood was collected every month (m) after transplantation. Half of
the mice receiving LV/AGA-transduced cells were killed 3 months post-transplant, and the other half were killed 6 months post-transplant. (A–D) a-Gal A activity from plasma
(A), PBMCs and BM (B), and four major organs (C) was determined, and total Gb3 levels in tissues from the organs (D) were measured by mass spectrometry as described in
Materials and Methods. Error bars show ± SEM. Data from the mock-transduced group of mice were compared with the LV/AGA-transduced group at each time point, and
only p values that were less than 0.05 are shown. (E) Average VCN per genome from PBMCs, BM, and organs of all mice at different collection points was determined by
quantitative real-time PCR as described in Materials and Methods.
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produced by the IUVPF produced functional a-gal A enzyme in xen-
otransplanted mice sufﬁcient to correct Gb3 accumulation in spleens
and livers with only an 20% BM engraftment rate.
LV Integration Profile and Genotoxicity Analysis
An in vitro immortalization (IVIM) assay was performed to test
the potential genotoxicity of our therapeutically directed LV vector.
This is an insertional mutagenesis assay that evaluates the transfor-
mation potential of candidate recombinant lentiviruses. The LV
that we tested was LV/FAB, which engineers expression of a cell
fate control cassette (DLNGFR/TMPK)16 upstream of the codon-
optimized cDNA of the GLA gene in a bicistronic format.16 This vec-
tor is an early-version LV designed by our group that has the identical
backbone as our current therapeutic version, LV/AGA, plus the IRES
element and our patented cell-fate control element.
Two rounds of transduction into primary murine lineage marker-
negative (Lin) BM cells were performed to reach 2–10 VCN/
genome. The vectors selected for this assay included LV/FAB, control
LV/RRL.PPT.SF.eGFP.pre* (lv-SF), which is a self-inactivating vector
expressing EGFP under the control of the strong internal retroviral
enhancer/promoter from the spleen focus-forming virus, and a posi-
tive control g-retroviral vector, pRSF91.GFPgPRE (RSF91).28 After
15 days of culture, transduced cells were diluted and reseeded at
low cell density. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay was performed after 2 additional weeks
of clonal expansion as described in Materials and Methods.
Replating frequency (RF) was calculated from the wells demon-
strating clonal expansion in each assay (Materials and Methods).
No clonal expansion was observed from mock-transduced cells. In
contrast, cells transduced with the positive control vectors RSF91
(0.0016 RF/VCN) and lv-SF-(0.000091 RF/VCN) displayed robust
transformation.28 More importantly, cells transduced with LV/FAB
only displayed 0.000036 RF/VCN, 40-fold lower than Lin cells
transduced with the g-retroviral vector RSF91 and at the limit of
detection of the assay. Furthermore, the incidence of positively
scoring assays was signiﬁcantly lower for LV/FAB compared with
control lv-SF.
Genomic DNA was extracted from highly proliferating LV/FAB-
transduced cells for linear ampliﬁcation-mediated PCR (LAM-PCR)
analysis as described elsewhere.28 A non-speciﬁc background smear
was observed from DNA isolated from mock-transduced cells (Fig-
ure 5A). DNA isolated from three of ﬁve expanded clones (clones
3, 4, and 5 corresponding to gel lanes 1, 2, and 3, respectively) gener-
ated multiple bands on the gel, suggesting random viral integration.
Two other clones (clones 6 and 7 corresponding to gel lanes 4 and
5, respectively) did not yield prominent bands. DNA bands from
clones 3, 4, and 5 were cut from the gel, puriﬁed, and sequenced.
As shown in Figure 5A, the DNA bands labeled with red numbers
showed low sequencing quality and had no clear match to the murine
genome or they matched the vector backbone sequence. Green
numbers indicate successful BLAST results for identiﬁcation of the
integration sites. The sequencing results, including Entrez Gene ID,
the chromosomal location, raw distance of the insertion site to the
next gene, and distance to the transcriptional start site (TSS) of that
gene, are listed in Table S1.
Validation of LV Transduction Scale-Up and Cell Production
under GMP Conditions
To fulﬁll the requirements for clinical implementation, we developed
an LV/AGA scaled-up transduction protocol under GMP conditions
at the UHN Philip S. Orsino Cell Therapy Facility. Fifty million cry-
opreserved Fabry patient (no. 15-220) CD34+ hematopoietic cells
were thawed and cultured in stem cell growth medium (SCGM) sup-
plemented with GMP-grade cytokines in a VueLife cell culture bag at
a density of 1  106 cells/mL for 24 hr. Then the near-clinical-grade
LV/AGA was added to the cell culture to reach an MOI of 10. After
overnight transduction, cells were washed twice with Plasma-Lyte
A plus 0.5% human serum. Twomillion cells were split off and placed
in complete SCGM (cSCGM) for additional analyses. The remaining
cells were pelleted and resuspended in a cryopreservation solution,
CryoStor CS10, to maintain a cell density of 2–10  106 cells/mL.
The ﬁnal cell suspension was cryopreserved in an OriGen CryoStore
freezing bag and stored in the vapor phase of the liquid nitrogen tank.
Quality control (QC) tests were performed on aliquots of the ﬁnal
cell product to ensure that the standards of cell therapy products
were met.
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Figure 3. Engraftment of Fabry Patient CD34+ Hematopoietic Cells in NSF Mice
(A–C) Mobilized CD34+ hematopoietic cells from Fabry patient no. 15-220 were mock-transduced (mock) or transduced with the near-clinical-grade LV/AGA and then
injected into conditioned male NSF mice. Peripheral blood was collected 4 weeks (wk) post-transplant and every 2 weeks after that until the mice were terminated 12 weeks
after transplant. PBMCs (A) and BM cells (B and C) were stained with PE-conjugated anti-human CD45 antibody or PE-labeled anti-human CD34 antibody, and the per-
centage of CD45+ or CD34+ cells was quantified by flow cytometry. Error bar: mean ± SEM.
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Figure 4. In Vivo Correction of a-Gal A Deficiency by Xenotransplanted LV/AGA-Transduced Fabry Patient CD34+ Hematopoietic Cells in NSF Mice
a-Gal A activity in plasma (A), BM (B), and four major organs (C) from NSF mice described in Figure 3 was measured by enzyme assay, and total Gb3 levels in the organs (D)
were measured by mass spectrometry as described in Materials and Methods. Bars show ± SEM. The data from the mock group mice were compared with the LV/AGA
group at each time point, and only p values that were less than 0.05 are shown. Negative a-gal A activity obtained from several plasma samples is presented as 0 nmol/hr/mL
and was not included in the statistical analysis. The total Gb3 level is the sum of relative abundances of different Gb3 isoforms, which were expressed as their peak areas
divided by the peak area of the internal standard (area/area IS) as described in Materials and Methods. (E) Average VCN per genome from BM and organs of all mice at
different collection points was determined by quantitative real-time PCR as described in Materials and Methods.
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A portion of the 2  106 cells harvested post-transduction was sub-
jected to a CFC assay; the remaining cells were kept in culture for 4
more days. Supernatants and a cell pellet were then collected and tested
for a-gal A activity as well as for an average VCN per cell. We carried
out two independent validation runs (engineering runs) following the
above protocol utilizing our approved standard operating procedures
(SOPs). The results of the corresponding analyses are listed in
Table 2. Total cell viability during the 3-day processes was maintained
at 90% and above. The long-term transduction efﬁciency as evaluated
by CFC assay was found to be 67.9% from the ﬁrst engineering run
and 29.8% from the second. A similar viral integration frequency was
observed from both runs, an average of 0.59 VCN/genome from the
ﬁrst run and0.51VCN/genome from the second.a-GalA activity levels
in both the culture supernatant and lysates were much higher than
basal activity levels in non-transduced cells (Table 2; Figure 1D). These
results indicated successful scale-up clinical transductions with mobi-
lized Fabry patient CD34+ hematopoietic cells.
Finally, to test the stability of the cryopreserved cell product, we
thawed the cell product after 1-week storage in vapor phase liquid
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Figure 5. In Vitro Genotoxicity of LV/FAB and In Vivo Toxicity in Livers of NSF Mice Xenotransplanted with LV/AGA-Transduced Mobilized Fabry Patient
CD34+ Hematopoietic Cells
An IVIM assay was carried out to examine the in vitro genotoxicity of LV/FAB as described in Materials and Methods. (A) The five clones from LV/FAB-transduced mouse BM
cells that showed growth were analyzed by LAM-PCR. PCR products were run on a 2% agarose gel (lanes 1–5, clones 3–7; lane 6, mock; lane 7, 1-kb DNA ladder).
Prominent DNA bands were cut out and sequenced. Bands with green numbers show that the sequence was identified by BLAST in the mouse genome; bands with red
numbers show that the sequence had low quality or no match to the mouse genome. (B) The toxicology study in NSF mice was carried out as described in Materials and
Methods. Organs collected on day 7 or day 28 post-transplantation were fixed, sectioned, and stained with H&E for microscopic evaluation. Liver sections from all animals
were evaluated for signs of hepatic injury, inflammation, neoplasia and/or degeneration. Representative images of liver sections are shown with each mouse code number
next to each image. H&E magnification 100.
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nitrogen and examined cell viability up to 24 hr post-thawing. The
viability of the thawed cells was maintained above 80% up to 6 hr
post-thawing but decreased below 80% at 24 hr post-thawing from
both engineering runs (Table 3).
In Vivo Toxicology Study of Our Therapeutic Product: LV/AGA-
Transduced Fabry Patient CD34+ Hematopoietic Cells
To investigate the potential in vivo toxicity of the LV/AGA-trans-
duced Fabry patient CD34+ hematopoietic cell product, we used
our NSF mouse model for an additional xenograft study. To do this
under optimal conditions, the NSF mouse line was re-derived at the
Toronto Centre for Phenogenomics (TCP) behind a barrier, and a
cohort of 7-week-old mixed-gender mice was selected for these exper-
iments. CD34+ hematopoietic cells isolated from a Fabry patient (no.
15-220) were transduced overnight with vehicle (mock) or LV/AGA
at an MOI of 10, and 1  106 cells were infused into recipient mice
1 day after they were irradiated and treated with antibody against
mouse CD122.15 Half of the mice were killed on day 7, and the
remainder were killed on day 28. Mouse weight, body and dermal
condition, general appearance, behavior, metabolic parameters, and
complete blood counts were assessed.
No overt differences were observed between male and female mice at
any of the time points; consequently, the data were pooled from both
genders. All mice displayed normal weight gain and dermal condition
throughout the course of these analyses. Two LV/AGA group male
mice displayed hyperactivity and nervous behavior, whereas all other
mice were normal. Four LV/AGA group male mice had rufﬂed fur,
and two LV/AGA group male mice showed rufﬂed fur as well as a
slightly hunched posture. Two LV/AGA group females displayed
rufﬂed fur. One mock group animal had rufﬂed fur and a slightly
hunched posture. Analyses of biochemical parameters revealed
that the mice with rufﬂed fur and a hunched posture had elevated
levels of alanine aminotransferase (ALT), aspartate aminotransferase
(AST), and total bilirubin, suggesting that mild liver damage occurred
in both LV/AGA-treated and mock-treated animals. Analyses of liver
histology showed no abnormalities in either group of mice and no
obvious difference between groups (Figure 5B), except in liver sec-
tions from one animal from the LV/AGA group, where there was a
focal area of acute subcapsular hepatic hemorrhage (data not shown).
This change was interpreted to be most consistent with terminal
handling and unrelated to gene therapy treatment.
Analyses of blood biochemistry parameters revealed no signiﬁcant
differences between mock and LV/AGA mice on either day 7
or day 28 (Table S2). Urinary glucose, urinary nitrite, urinary protein,
blood hemoglobin, and urinary leukocytes were examined on
days 2, 7, and 28. No overt differences in any of these parameters
were observed at any time points in mock or LV/AGA group mice
(data not shown).
Both LV/AGA and mock control mice displayed typical radiation-
induced cytopenia on day 7 (Table S3). Interestingly, LV/AGA
mice had increased platelets compared with mock-transplanted con-
trols on Day 7 (Figure S3A). Whether the radiation-induced nadir
was lower or the timeline of platelet recovery was altered is difﬁcult
to ascertain with a single time point. Parallel decreases in erythro-
cytes, lymphocytes, neutrophils, monocytes, basophils, and eosino-
phils were observed in all animals.
LV/AGA mice displayed slight anemia on day 28. Both LV/AGA and
mock mice had elevated red blood cell (RBC) distribution width on
day 28. Thrombocytopenia was observed in both groups of mice on
day 28. Control mice had lower numbers of lymphocytes, neutrophils,
and monocytes on day 28, suggesting that these animals had not
recovered as quickly from cytopenia associated with radiation and
the subsequent BMT (Table S4; Figure S3B). In sum, no signiﬁcant
toxic effects were observed in NSF mice receiving LV/AGA-trans-
duced Fabry patient CD34+ hematopoietic cells.
DISCUSSION
ERT for Fabry disease still has substantial limitations. Intravenous
enzyme infusions are required every 2 weeks for life. The procedure
time and travel to an infusion center or hospital along with chronic
intravenous access issues (in some patients a permanent in-dwelling
catheter is surgically inserted) are problematic. In Canada, the costs of
ERT alone can exceed $300,000/patient/year. Inactivating antibodies
can also develop against the infused product that could theoretically
limit drug action. To date, ﬁve randomized, placebo-controlled ERT
trials in a total of 239 patients, with extension trials and data from
multi-national registries of Fabry patients, have shown only modest
improvements in left ventricular mass, stabilization of renal function,
quality of life, lessening of neuropathic pain, and reduction of Gb3 in
tissues, plasma, and urine.29–37
Gene therapy has the potential to offer a sustained therapeutic
response in Fabry disease with a minimal number of treatments
and lower costs. Trials have been undertaken in children in Milan
for two other lysosomal storage disorders (LSDs) to examine feasi-
bility/safety; patients have been treated by LV-mediated gene transfer
targeting primitive hematopoietic cells for metachromatic leukodys-
trophy (MLD)38 and globoid cell leukodystrophy (GLD).39 The re-
sults from the MLD trial have demonstrated short-term safety and
Table 2. Analysis of Scale-up Transduction of Fabry Patient CD34+ Cells
Analysis Eng. Run 1 Eng. Run 2
VCN/genome 0.59 0.51
Percentage of transduced cells by CFC 67.9 29.8
a-Gal A activity in supernatant (nmol/hr/mL) 13.15 63.0
a-Gal A activity in cell pellet (nmol/hr/mg protein) 1,888.14 6,517.8
Cell viability during cell processing (%)
Day 1 (at thaw) 98 96.6
Day 2 (before transduction) 92.5 91.5
Day 3 (before resuspension in freezing medium) 97 89.5
Eng. Run, engineering run.
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a high sustained level of gene marking and associated enzyme
activity.38
Previous studies from our group demonstrated long-term enzyme
correction and lipid reductions in Fabry mice treated with direct
injections of a recombinant LV engineering expression of a-gal A26
or with LV-transduced murine HSCs.24 In the latter study, even
low MOIs led to high levels of intracellular and secreted a-gal A ac-
tivity. Organ enzyme activity was high 24 weeks after transplant of
LV-transduced mouse BM cells, and secondary transplants led to
increased a-gal A activity a full 20 weeks after infusion of cells
from donor animals.24 We have also shown successful engraftment
of LV-transduced human normal CD34+ hematopoietic cells in
NSF mice and a-gal A correction in several major organs.15 To eval-
uate gene therapy for treating Fabry patients, we are initiating a ﬁrst-
in-the-world pilot gene therapy trial for Fabry disease.
Because the primary endpoint of our clinical study is the evaluation of
the safety of this approach, we originally designed a bicistronic vector,
LV/FAB (and LV/FAB-2), containing a cell-fate control element that
can selectively eliminate transduced cells if they become oncogenic
in vivo.16 Meanwhile, we examined the viral integration proﬁle in ge-
nomes of transduced mouse BM progenitor cells, and LV/FAB
showed a signiﬁcantly lower risk of inducing clonal outgrowth than
a control g-retroviral vector or another lentivector (lv-SF) that uses
the strong internal retroviral enhancer/promoter from the spleen
focus-forming virus.
The functionality of our clinically directed LV is another important
factor for our proposed trial because the systemic therapeutic effect
depends on the level of a-gal A expression from the transduced pa-
tient CD34+ hematopoietic cells. Fabry patient CD34+ hematopoietic
cells transduced with LV/FAB only produced a 10%–20% a-gal A
activity level of that from normal CD34+ cells, however. To improve
the vector efﬁcacy, we optimized the consensus Kozak sequence
in the transfer vector for LV/FAB and made another LV/a-gal,
A.IRES.hCD25, in which the cDNA encoding a-gal A is directly un-
der the control of the EF-1a promoter. It turned out that Fabry pa-
tient CD34+ hematopoietic cells transduced with these vectors still
did not express a level of active a-gal A activity comparable with
normal cells. We speculated that the IRES-mediated bicistronic sys-
tem might negatively affect the expression of a-gal A. Therefore,
ﬁnally, we constructed a simple transfer vector with only a codon-
optimized human cDNA encoding a-gal A as the transgene. The re-
sulting LV/AGA showed much better efﬁcacy because LV-transduced
Fabry patient CD34+ cells produced higher-than-normal cell levels of
a-gal A activity. We further investigated the efﬁcacy of LV/AGA
in Fabry patient CD34+ hematopoietic cells both ex vivo and in a xe-
notransplant mouse model. This shows, for the ﬁrst time, that the
therapeutic product, LV/AGA-transduced Fabry patient CD34+ he-
matopoietic cells, produced functional a-gal A activity in an animal
model and achieved enzyme correction and lipid reduction in tissues.
The development of the safe and efﬁcient clinically directed LV/AGA
and pre-clinical results from it were critical for approval of our pilot
gene therapy trial for the treatment of Fabry patients.
There was no overt LV/AGA-related toxicity observed in any mu-
rine experiments except possible immunogenicity-related reactions
against the human protein. In the Fabry mouse-to mouse transplant
experiment, we observed that one mouse from the LV/AGA group
spontaneously died 9 weeks after transplant. This mouse developed
ulcerative skin dermatitis on the neck and top back. We also observed
various degrees of ulcerative dermatitis and ulcerative cornea in four
of ﬁve mice from the mock group and six of ten mice from the LV/
AGA group. Two mice from the LV/AGA group showed more severe
ulcers and had to be euthanized around 10 weeks after transplant ac-
cording to our UHN animal use protocol. These symptoms were also
observed in mice from the mock group that received donor cells
without LV transduction. Therefore, the ulcerative phenomenon is
likely caused by irradiation or our transplantation protocol itself.
The relatively more severe ulcerative pathology in the LV/AGA group
mice may be due to manifestations of graft-versus-host disease
because these mice received cells that express human a-gal A, and
the research-grade LV prep we used for this study may also contain
residual host cell (HEK293T) protein and DNA that is immunogenic
to mice. The ulcerative dermatitis symptom was not observed in the
NSF mice xenotransplant experiment, in which the mice are immu-
nodeﬁcient and transplanted cells were transduced with the near-clin-
ical grade LV that has minimal host cell contaminants, as analyzed/
approved by QC tests. In these NSF mice, we observed that two
mice from the mock group and two mice from the LV/AGA group
spontaneously died within 1 month after transplant, possibly because
of inefﬁcient engraftment or accidental infections in these mice. One
mouse from the mock group was very sick 6 weeks post-transplant
and was euthanized prematurely according to the UHN animal use
protocol. All other mice remained healthy until the endpoint, when
they were terminated for tissue collection.
We also performed IVIM experiments to investigate possible geno-
toxicity caused by LV integration. A caveat of this approach is that
higher MOIs than we are planning for the actual clinical trial are
necessary to perform an exhaustive insertion site analysis in concert
Table 3. Stability of the Cryopreserved Cell Product
At Thaw Time after Thaw (hr)
Time of Cell Counting 1 2 3 4 5 6 24
Eng. run 1 cell viability (%) 98.6 97.8 97.2 94.9 89.1 94.5 96.1 58.1
Eng. run 2 cell viability (%) 83 90.7 90.9 88.2 89.2 82.2 86.9 78.2
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with high-throughput sequencing. Four clones were successfully
sequenced from LV/FAB-transduced murine cells and showed clear
identity in the mouse genome. Two intronic inserts were observed
in mouse chromosome 10 for LV/FAB-transduced samples. Insertion
in PDE7B (phosphodiesterase 7B; sequence 3, lane 1) is closest to
AHI1 (Abelson helper integration site-1) for which we observed an
intronic hit in sequence 18 (lane 2). The AHI1 gene belongs to a fam-
ily of modular proteins containing one SH3 motif and seven WD40
repeats. AHI1 was originally identiﬁed as a target of proviral integra-
tion in murine leukemia40 and is a target of retroviral mutagenesis.41
Jiang et al.41 have shown that AHI1 collaborates with BCR-ABL in a
mouse model of leukemogenesis. Although Ahi1 has been shown to
play a role in mouse leukemogenesis, there is limited evidence that
mutation of AHI1 is relevant in human cancer. Only one mutation,
T1034A, has been documented in two patients in 2,139 sequencing
studies reported in hematopoietic and lymphoid malignancies
deposited in the online database Catalogue of Somatic Mutations in
Cancer (COSMIC). Biallelic mutation of AHI1 has been documented
in consanguineous families, leading to Joubert syndrome (JBTS3),
marked by hypotonia and developmental delay, among other
symptoms.42,43
Two fragments of the same insertion site were identiﬁed upstream
of HEY1 (lane 3, sequences 14 and 17). HEY1 (hairy/enhancer-of-
split related with YRPW motif 1) is a downstream target of Notch
signaling.44 The related family member, HEY2, maps adjacent to
HEY1 on mouse chromosome 3. The two Hey genes play a redun-
dant role in facilitating Notch-dependent signals.44 HEY1-NCOA2
chromosomal translocations are observed in human mesenchymal
chondrosarcomas.45 HEY1 provides a helix-loop-helix oligomeriza-
tion interface and is not transcriptionally active in this setting.
There is no evidence for mutation of HEY1 in hematopoietic or
lymphoid neoplasms in the 2,139 studies deposited in COSMIC.
Although the NOTCH pathway plays a role in T cell-mediated acute
lymphoid leukemia, it is unclear what the function of a low-fre-
quency integration into the HEY1 locus would be. Although integra-
tion into loci with a documented role in oncology was observed in
the IVIM assay, it is important to note that the events occurred in
intragenic or intronic regions, in keeping with published studies
indicating that LVs do not preferentially integrate into promoter
regions,38,46,47 a clear improvement over previous oncoretroviral
strategies.
LV-mediated gene delivery has several advantages over previous de-
livery platforms. Most notably, LVs have been demonstrated to be
safe in the clinic to date. We have selected Fabry disease for an initial
clinical study because we believe that wide ranges of a-gal A expres-
sion are very well tolerated and that patients with Fabry disease
mainly lack primary CNS symptoms. In this study, we showed that
therapeutic LV/AGA-transduced patient CD34+ hematopoietic cells
produce efﬁcient functional a-gal A activity and displayed minimal
toxicity in two different mouse models. We successfully developed
a large-scale ex vivo culture and LV transduction process on Fabry pa-
tient CD34+ hematopoietic cells to fulﬁll pre-clinical requirements.
We are conﬁdent from these preclinical data that gene therapy holds
promise for treatment of this disorder.
MATERIALS AND METHODS
Reagents
Phycoerythrin (PE)-labeled mouse anti-human CD45 and CD34
antibodies along with mouse immunoglobulin 1 (IgG1) k isotype
(all from BD Biosciences) were used for ﬂow cytometry. Anti-mouse
CD122 antibody (clone TM-b1) for in vivo depletion of NK cells was
purchased from BioLegend. Research-grade human stem cell factor
(SCF), FLT3L, thrombopoietin (TPO), interleukin-3 (IL-3), and
GMP-grade SCF and IL-3 were from R&D Systems. GMP-grade
human FLT3L and TPO were from CellGenix. Recombinant mouse
cytokines, SCF, FLT3L, TPO, and IL-6 were from R&D Systems. Hu-
man Serum Plus was from GEMINI Bio Products. Trypan blue stain
(0.4%), fetal bovine serum, and goat serum were from Life Technol-
ogies. The chemicals used in this study included 5-FU (Sigma-
Aldrich), protamine sulfate (Sigma-Aldrich and Fresenius Kabi
Canada), NycoPrep 1.077A (AXIS-SHIELD), 4-methylumbelliferyl-
a-D-galactopyranoside (Research Products International), N-acetyl-
D-galactosamine (Sigma-Aldrich), BSA (BioShop), and Proteinase
K (Invitrogen).
N-Octadecanoyl-D3-ceramide trihexoside (Gb3[(d18:1)(C18:0)D3],
98+%), heptadecanoyl-ceramide trihexoside (Gb3(d18:1)(C17:0),
98+%), and ceramide trihexoside (Gb3 isoform/analog mixture)
were purchased from Matreya. High-performance liquid chroma-
tography (HPLC)-grade tert-butyl methyl ether (MTBE) was from
Sigma-Aldrich. HPLC-grade methanol (MeOH) was from EMD
Chemicals. Optima liquid chromatography-MS (LC-MS)-grade wa-
ter, ammonium formate (Amm. Form., 99%), and American Chem-
ical Society (ACS) reagent grades for both glacial acetic acid and
potassium hydroxide (KOH) pellets were from Fisher Scientiﬁc. For-
mic acid (FA) (+99%) was from Acros Organics.
Stem Cell Mobilization and Leukapheresis
All studies involving patient samples were approved by the research
ethics boards of UHN, Alberta Children’s Hospital, and McMaster
University. Fabry patients were guided through the informed consent
process for this study by qualiﬁed personnel at the Alberta Children’s
Hospital. To collect mobilized peripheral blood CD34+ cells, Fabry
patients underwent stem cell mobilization via treatment with Granu-
locyte Colony Stimulating Factor (G-CSF, aka Neupogen, AMGEN)
using standard of care procedures offered at the Foothills Medical
Center. A dosage of 16 mg/kg G-CSF was administered intravenously
daily for 4 days prior to collection and on each day of collection for a
maximum of 3 days.
Leukapheresis was carried out through patient central or peripheral
venous access using a Spectra Optia system (Terumo BCT) according
to the SOP for collection of stem cell products at the Foothills Medical
Center. Mononuclear cells were collected into sterile leukapheresis
bags. At the end of each collection day, harvested cells were stored
in a temperature-controlled cooler and transported on the same
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day to the Juravinski Cancer Centre. A total of 3 continuous days of
collection was performed for each patient; day 1 and day 2 collections
were transported to the Juravinski Cancer Centre for CD34+ stem/
progenitor cell isolation.
Isolation of CD34+ Cells from the Leukapheresis Product
A CliniMACS CD34+ reagent system (Miltenyi Biotec) was used to
isolate CD34+ hematopoietic stem/progenitor cells at the Juravinski
Cancer Centre (using established SOPs) from the leukapheresis prod-
uct harvested on the previous day. After magnetic labeling with an
anti-human CD34 antibody, the CD34+ hematopoietic cells were en-
riched using a high-gradient magnetic separation column connected
to a closed disposable tubing set. After washing steps, the retained
CD34+ hematopoietic cells were eluted by removal of the magnetic
ﬁeld. The degree of puriﬁcation was monitored by ﬂow cytometry
analysis after staining an aliquot of puriﬁed product with a two-color
ﬂuorescein isothiocyanate (FITC)-CD45/PE-CD34 reagent from the
Stem-Kit (Beckman Coulter).
Isolated CD34+ cells were immediately resuspended in 10% Cryoserv
DMSO (Bioniche PHARMA) plus 10% autologous plasma and 80%
Plasma-Lyte A (Baxter) in CryoStore freezing bags (OriGen Biomed-
ical) and cryopreserved using a controlled-rate freezer (Planer).
Following this, the cells were stored in the vapor phase of a liquid ni-
trogen tank. The cryopreserved CD34+ cells were later transported to
our laboratory at UHN or directly to the Philip S. Orsino Cell Process-
ing Facility at Princess Margaret Hospital for LV transduction.
Cell Culture
HEK293T cells were cultured in DMEM (Gibco by Life Technologies)
supplemented with 10% fetal bovine serum and 1 penicillin-strep-
tomycin-glutamine (PSQ) (2 mM glutamine, 100 U/mL penicillin,
and 100 mg/mL streptomycin; Gibco by Life Technologies).
Mobilized peripheral blood normal CD34+ cells from healthy donors
were purchased from AllCells. Human primary CD34+ cells were
cultured in CellGro stem cell growth medium supplemented with
300 ng/mL recombinant human SCF, 300 ng/mL recombinant
human FLT3L, 100 ng/mL human TPO, and 60 ng/mL recombinant
human IL-3.
Mouse primary bone marrow PBMCs were cultured in CellGro stem
cell growth medium supplemented with 100 ng/mL recombinant
mouse SCF, 100 ng/mL recombinant mouse FLT3L, 100 ng/mL
mouse TPO, and 10 ng/mL mouse IL-6.
All cells were maintained in a humidiﬁed incubator at 37C with
5% CO2.
LV Construction
A DNA fragment comprising the Kozak sequence and the cDNA of
the humanGLA gene encoding a-gal A was synthesized by GenScript.
The cDNA of the GLA gene was codon-optimized for enhanced
expression in human cells. The synthesized DNA fragment was subcl-
oned into the 30 self-inactivating (30SIN), HIV-1-based, lentiviral
backbone pDY.cPPT-EF1a.WPRE previously generated in our labo-
ratory16 between the EcoRI and XmaI restriction sites to generate the
plasmid pDY.CO.a-gal A. We later observed that the Kozak sequence
in this construct was not optimal because of a missing guanine nucle-
otide at the6 bp position before the start codon. To avoid a potential
reduction in gene expression, an optimal Kozak sequence was engi-
neered in the plasmid by site-directed mutagenesis using the Q5
site-directed mutagenesis kit (New England Biolabs). The ﬁxed
pDY.CO.a-gal A plasmid was used for all LV preparations in this
study. The plasmid sequence covering the proviral region was veriﬁed
by DNA sequencing.
Purification of Research-Grade and Near-Clinical-Grade LV
along with Functional Titer Analyses
Research-grade LV/AGA was prepared in our laboratory at UHN as
described previously.48 Near-clinical-grade LV/AGAwas produced at
the IUVPF, which meets current GMP requirements for potential
human clinical trial use under an investigational new drug (IND) sub-
mission. The LV particles were produced using HEK293T packaging
cells from a certiﬁed master working cell bank maintained by the
IUVPF. The packaging cells were expanded to a 4-L culture volume
and transiently co-transfected with the LV packaging plasmids
(pCMVDR8.91 and pMDG) and transfer plasmid (pDY.CO.a-gal
A) provided by our laboratory. The sequences of those plasmids
that were expanded at IUVPF were veriﬁed by DNA sequencing at
ACGT. Culture supernatant was harvested twice, yielding a total of
8 L of unconcentrated LV-containing supernatant. The LV-contain-
ing supernatant was further puriﬁed by Mustang Q ion exchange
chromatography, concentrated by tangential ﬂow ﬁltration, and
buffer-exchanged into 100 mL GMP-grade CellGrow stem cell
growth medium.
Sample vials of the ﬁnal concentrated vector product were retained by
the IUVPF for QC analyses, including vector identity conﬁrmation by
Southern blot analysis and titer by p24 ELISA, along with testing for
aerobic and anaerobic sterility, mycoplasma levels, endotoxin levels,
and residual DNA benzonase levels.
We performed infectious titer testing at our UHN laboratory on all
LV preparations by transduction of HEK293T cells using serial dilu-
tions of the vector followed by measurement of average proviral copy
number per cell using quantitative real-time PCR analysis (see below).
LV Transduction
Frozen CD34+ hematopoietic cells from Fabry patients enrolled for
this study as well as from healthy donors purchased from AllCell
Technologies were quickly thawed at 37C, washed with SCGM,
and cultured in complete SCGM for 24 hr at a density of 1  106
cells/mL. For small-scale transductions, cells were pelleted by
centrifugation at 300  g for 10 min at room temperature. The cell
pellet was then resuspended in complete SCGM containing the LV/
AGA preparation and protamine sulfate (ﬁnal concentration at
8 mg/mL) to reach an MOI of 10 and to maintain a ﬁnal cell density
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of 1  106 cells/mL. Cells were put in appropriate sterile culture
vessels to keep a (culture volume)/(vessel surface area) ratio of
9.62 cm2/mL ± 10% to allow consistent contact between LV particles
and cells. Cells were incubated in a humidiﬁed 37C and 5% CO2
incubator overnight, washed, and resuspended in fresh complete
growth medium for 2 or 4 more days.
For large-scale transduction experiments carried out in the Philip S.
Orsino GMP-compliant facility in Princess Margaret Hospital, 50–
80 106 cells were thawed and cultured for 24 hr in complete growth
medium in VueLife cell culture bags (Saint-Goubain) to maintain the
depth of cell suspension between 0.3 and 0.5 cm. Protamine sulfate
was added to the cell suspension, mixed, and followed by addition
of the near-clinical-grade LV/AGA viral preparation to reach an
MOI of 10. After a 16- to 18-hr overnight transduction, cells were
transferred into 500-mL conical tubes and centrifuged at 300  g
for 10 min. The cell pellet was resuspended in wash buffer (Plasma-
Lyte A containing 0.5% Human Serum Plus) and washed twice to re-
move residual LV particles. An aliquot of cell suspension was grown
for an additional 4 days at our UHN laboratory; culture supernatants
and cell pellets were collected at the end of the growth period for a-gal
A enzyme assays and qPCR analyses. The remaining post-transduc-
tion cells were resuspended in CryoStor CS10 (BioLife Solutions)
freezing medium and transferred into CryoStore freezing bags
(OriGen Biomedical). Aliquots of the cell product were sampled for
QC testing for microbiology (Department of Microbiology, Mount
Sinai Hospital) and mycoplasma (WuXi AppTec) sterility, endotoxin
level (Endosafe-PTS system, Charles River Laboratories; performed
by Translational Immunotherapy Laboratory, Immune Therapy Pro-
gram, Princess Margaret Hospital) and cell viability (in our laboratory
at UHN).
Measurement of a-gal A Activity
The assay used to measure a-gal A activity was described previ-
ously.26 Basically, cells or tissues were lysed by freezing/thawing
or by Dounce homogenization in cell homogenization buffer
(CHB; 28 mmol/L citric acid, 44 mmol/L disodium phosphate, and
5 mg/mL sodium taurocholate). After centrifugation, clear lysates
were incubated with a-gal A substrate solution (5 mmol/L 4-methyl-
umbelliferyl-a-D-galactopyranoside, 100 mmol/L N-acetyl-D-galac-
tosamine, and 4 mg/mL BSA) at 37C for 1–4 hr. Stop solution (1.1
mol/L glycine and 0.1 mol/L NaOH) was then added to the reaction.
The ﬂuorescence from each reaction in a plate was measured on a mi-
crotiter plate ﬂuorometer (DYNEX Technologies) with excitation at
350 nm and emission at 460 nm. Serially diluted 4-methylumbellifer-
one (Sigma-Aldrich) solutions were used as standards. CHB buffer
was used as a blank for cell lysates, and heat-inactivated pooled Fabry
mouse plasma was used as a blank for plasma samples.
Quantitative Real-Time PCR
Four days after transduction, cells were collected and washed once in
PBS. 1  106 cells were processed for genomic DNA extraction using
the Gentra Puregene cell kit (QIAGEN) according to the manufac-
turer’s instructions. A set of primers (WPRE-RT-F, 50 TCCTGG
TTGCTGTCTCTTTATG 30; WPRE-RT-R, 50 TGACAGGTGGTG
GCAATG 30) and a TaqMan probe (50 FAM-TGCTGACGCA
ACCCCCACTGGT-TAMRA 30, synthesized by Life Technologies)
that target a LV-speciﬁc region (i.e., the WPRE) were used for the
real-time PCR reaction.
Fifty nanograms of genomic DNA prepared from a myeloid cell clone
containing one-copy LV integration (established in our laboratory
and veriﬁed by Southern blot; data not shown) were serially diluted
with genomic DNA from a non-transduced clone to generate DNA
standards. Real-time PCR was performed on these DNA dilutions
to generate a standard curve of cycle threshold (Ct) value versus
VCN for quantiﬁcation of test samples in parallel. The vector copy
number in transduced cells (copy number per genome) was deter-
mined by plotting the Ct value from transduced cells against the
standard curve.
Human b-actin levels were detected with a TaqMan gene expression
assay kit (Life Technologies, 4331182, gene ID Hs03023880_g1) and
were used to normalize genomic DNA levels between test samples
and the standards.
Colony-Forming Cell Assay
After an overnight transduction, CD34+ hematopoietic cells were
washed once with SCGM and resuspended in complete SCGM to a
density of 1  106 cells/mL. 3  104 cells were transferred into a
1.5-mL microcentrifuge tube and mixed with 0.3 mL SCGM. The
cell suspension was added to a 3-mL MethoCult (STEMCELL Tech-
nologies, H4434)-containing sterile tube and mixed thoroughly by
vortexing. The mixture was dispensed into two 35-mm sterile culture
dishes at 1.1 mL/dish. The dishes were incubated in a humidiﬁed
37C, 5% CO2 incubator for 2 weeks. Single cell-derived colonies
were manually picked under a phase contrast light microscope and
lysed in colony lysis buffer (100 mM Tris-HCl [pH 8.5], 5 mM
EDTA, 0.2% SDS, 200 mM NaCl, and 0.41 mg/mL Proteinase K).
Colony lysates were subjected to endpoint PCR to detect the presence
of the LV-speciﬁc element, WPRE, with primer sets (WPRE-RT-F2:
50-TCCTGGTTGCTGTCTCTTTATG-30 and WPRE-RT-R2: 50-TG
ACAGGTGGTGGCAATG-30 or WPRE2 FW: 50CGCTGCTTT
AATGCCTTTG 30andWPRE2 REV: 50 AAGGGAGATCCGACTCG
TCT 30).
Ultra-Performance Liquid Chromatography/Tandem MS
Analysis of Gb3 Isoforms in Mouse Tissue Samples
A previously validated and published procedure49 was used for the
homogenization, extraction, and MS analysis of Gb3 isoforms in kid-
ney, liver, spleen, and heart tissue samples fromNSFmice. Brieﬂy, tis-
sue samples were homogenized in 400 mL of methanol at high speed
(5 m/s) with ﬁve zirconium oxide beads (1.4-mm diameter, Omni
International) for 45 s using a Bead Ruptor 12 homogenizer (Omni
International). Samples were diluted with methanol to reach a con-
centration of 2.5 mg/mL. Diluted homogenates (1 mL) were spiked
with 100 mL of Gb3[(d18:1)(C18:0)D3] (Matreya, 1 mg/100 mL) inter-
nal standard, saponiﬁed with KOH (1 M in methanol), and extracted
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withMTBE. The organic layers were evaporated to dryness and resus-
pended in 500 mL of methanol, 5 mM ammonium formate, and 0.1%
formic acid. Separation of the Gb3 isoforms was performed by ultra-
performance liquid chromatography (UPLC) (Acquity I-class, Wa-
ters) using a hollow structure section (HSS) T3 C18 column (Waters)
and analyzed by tandem MS (Xevo TQ-S, Waters) in multiple reac-
tion monitoring (MRM) mode with positive electrospray ionization.
Peak areas were measured using QuanLynx V4.1 software (Waters),
and relative abundances of different Gb3 isoforms were expressed
as their peak areas divided by the peak area of the internal standard.
Animals
Fabry hemizygous male and Fabry homozygous female mice that are
deﬁcient in a-gal A activity were generated previously.27 NOD/SCID/
Fabry (NSF) mice were generated previously by our group.15 All mice
were housed at the Animal Resource Centre at UHN or at the TCP
under speciﬁc pathogen-free conditions. All animal studies were
approved by the UHN and TCP Animal Care Committees.
Isolation of Mouse BMMNCs, LV Transduction, and BMT
BM cells were harvested from mixed-gender donor Fabry mice (8–
26 weeks old), and BM mononuclear cells (BMMNCs) were isolated
over a Nycoprep 1.077 density gradient as described previously.24
BMMNCs were washed with RPMI (Sigma-Aldrich) and resus-
pended in complete RPMI (10% fetal bovine serum [FBS] plus 1
PSQ), and live cells were quantiﬁed by trypan blue exclusion. Cells
were split into two tubes and centrifuged at 400  g for 10 min.
The cell pellet in the ﬁrst tube was resuspended in complete SCGM
(SCGM supplemented with mouse cytokines: 10 ng/mL recombinant
mouse (rm)IL-6, 100 ng/mL rmFLT3L, 100 ng/mL rmTPO, and
100 ng/mL rmSCF) and protamine sulfate (8 mg/mL) to reach a cell
density of 1  106 cells/mL (mock transduction). The cell pellet in
the second tube was resuspended in research-grade LV/AGA supple-
mented with complete SCGM and protamine sulfate to reach a cell
density of 1  106 cells/mL and MOI of 10 (LV/AGA transduction).
Cells were incubated overnight in a humidiﬁed incubator at 37C
with 5% CO2 for the transduction. The next morning, cells were
washed, counted, and resuspended in 1 PBS.
One million mock- or LV/AGA-transduced cells were injected via
the tail vein into lethally irradiated (11 Gy) recipient Fabry male
mice (8–15 weeks old). Recipient Fabry mice were randomized and
divided into three groups with 5 mice/group: mock group, mice
receiving mock-transduced donor cells; LV/AGA group (short-
term), mice receiving LV/AGA-transduced donor cells and sacriﬁced
12 weeks after transplantation; and LV/AGA group (long-term), mice
receiving LV/AGA-transduced donor cells and sacriﬁced 24 weeks
after transplantation.
Peripheral blood was collected from recipient mice by saphenous vein
blood draw every 4 weeks after transplant or by cardiac puncture at
termination. Plasma and cells were separated by centrifugation at
room temperature, and RBCs were lysed with RBC lysis buffer
(Sigma-Aldrich) to yield PBMCs.
NSF Mouse Xenotransplantation
NSF male mice (7–10 week old) received less-than-lethal irradiation
(3 Gy) and were injected intraperitoneally with a monoclonal anti-
body against mouse CD122 (200 mg/mouse) to deplete NK cells as
described previously.15 One day later, mice were injected via the tail
vein with mock or near clinical-grade LV/AGA-transduced Fabry
patient (no. 15-220) CD34+ hematopoietic cells (described in LV
Transduction). Mice were randomized and divided into two groups
with 8 mice/group: mock group, mice receiving mock-transduced
Fabry CD34+ cells; LV/AGA group, mice receiving LV/AGA-trans-
duced Fabry CD34+ cells. Mice were killed 12 weeks after transplant.
For the toxicology study, NSF mice were housed at TCP, and a cohort
of 7- to 8-week-old NSF male and female mice was acclimatized
for 6 days and subsequently xenotransplanted with Fabry CD34+ he-
matopoietic cells. Fabry patient (no. 15-220) CD34+ hematopoietic cells
were eithermock-transducedor transducedwith the near-clinical-grade
LV/AGA at anMOI of 10 in our laboratory and delivered toTCP on the
day of injection.Onemillion cells were injected into eachmouse, andwe
formed two treatment groups: mock group, mice receivingmock-trans-
duced cells; LV/AGA group, mice receiving LV/AGA-transduced cells.
All mice weremonitored daily, and body weight wasmeasured daily for
the ﬁrst week and once per week thereafter. A clinical assessment was
performed weekly and on the day of study termination. Half of the
mice in each group were killed on day 7 and the remainder on day 28.
On the day of study termination, urine and whole blood were collected
for urinalysis, hematology, and plasma chemistry analysis. A target or-
gan panel (brain, heart, lung, liver, spleen, kidney, testes or ovaries, and
bonemarrow)was collected for snap-freezing in LN2, followed by com-
plete necropsy with tissue collection for immersion ﬁxation in 10%
neutral buffered formalin. Fixed samples were trimmed, embedded in
parafﬁn wax, sectioned, and stained with H&E for microscopic evalua-
tion. The histopathology analyses of each tissue were reviewed by an
American Board of Toxicology-certiﬁed animal pathologist.
IVIM Assays
IVIM assays were carried out as described previously.28
Viral Transduction and Clonal Expansion of Murine BM Cells
Mouse Lin BM cells were isolated and kept at 80C overnight.
Cells were thawed the following day and seeded in a 24-well plate
at 1  105 cells/well in StemSpan medium supplemented with com-
plete growth medium supplement (CGMS; 1% penicillin/strepto-
mycin, 50 ng/mL mouse SCF, 100 ng/mL FLT-3L, 100 ng/mL
IL-11, and 20 ng/mL mouse IL-3; all from PeproTech) and incubated
for 2 days. Plates coated with Retronectin (Takara Bio) were used to
preload viral constructs, and the ﬁrst round of transduction was
completed with prestimulated Lin cells. A new Retronectin-coated
plate was used for preloading viral vectors on the following day
(day 0), and a second round of transduction was conducted by trans-
ferring transduced cells to the new plate. After overnight incubation,
cells were transferred to 12-well plates and cultured in Iscove’s modi-
ﬁed Dulbecco’s medium (IMDM; Biochrom) supplemented with
CGMS. After day 15, cells were seeded at 100 cells/well in 96-well
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plates and cultured for an additional 2 weeks. Trypan blue exclusion
counting was performed on days 1, 4, 6, 8, 11, and 15.
Measurement of VCN by Quantitative Real-Time PCR
Quantitative real-time PCR analysis was performed using genomic
DNA (100 ng) as a template to determine VCN per cell. Samples
were analyzed in triplicate. Proviral content was determined from
WPRE sequences, and the Ptbp2 gene (genomic reference sequence)
was used to normalize the total genomic DNA amount. Absolute
quantiﬁcation was measured by comparing serial dilutions of a
plasmid standard containing both sequences.
Identification of Clonal Expansion and Calculation of Replating
Frequencies
Outgrowth was determined initially by microscope, followed by
MTT assay. Prior research had demonstrated that 4 SD of all read-
ings reproduced the microscopic scoring and was determined as the
threshold value distinguished from background absorbance readings
in the MTT assay. If the measured absorbance was above the
threshold, then the well was scored as positive in the MTT matrix.
Clonal outgrowth was independently screened by two technologists
in four categories. Category 1 is a robust outgrowth with a visible
pH change of the medium. Category 2 is obvious outgrowth of cells.
Category 3 shows some level of proliferation and may be assigned to
category 2 in case of a positive result in the MTT assay. Category 4
shows no cell growth and scores as negative in the MTT assay.
The RF was calculated from the number of wells above threshold us-
ing the L-Calc software (version 1.1) from STEMCELL Technologies
according to Poisson distribution. The risk of insertional mutagenesis
was correlated to the number of vector copies per cell, and RFs were
normalized to the VCN.
Insertion Site Analysis
LAM-PCR50 was performed using genomic DNA (300 ng) as a tem-
plate. PCR amplicons were visualized on a 2% agarose gel. Speciﬁc
bands were excised, puriﬁed, and directly sequenced.
Flow Cytometry
PBMCs and BMMNCs were collected from mice at the time of anal-
ysis. RBCs were lysed in RBC lysing buffer (Sigma-Aldrich; 8.3 g/L
ammonium chloride in 0.01M Tris-HCl buffer [pH 7.5 ± 0.2])
according to the manufacturer’s instructions. Cells were washed
with 1 PBS and resuspended in ﬂuorescence-activated cell sorting
(FACS) buffer (PBS, 2% fetal bovine serum, 1 mmol/L ethylenediami-
netetraacetic acid, and 0.1%NaN3) on ice and stained with PE-hCD45
or PE-hCD34 or the corresponding isotype. Cells were then analyzed
by ﬂow cytometry using a FACSCalibur (BD Biosciences), and data
were analyzed by CellQuestPro and FlowJo software.
Statistical Analysis
Results are expressed as mean ± SD or SEM as indicated. Differences
between groups were assessed using Student’s t test or ANOVA.
Values of p < 0.05 were considered to be signiﬁcantly different.
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